
Baxter (BAX) Stock Forecast & Price Target
Baxter (BAX) Analyst Ratings
Bulls say
Baxter International's Healthcare Systems & Technologies segment demonstrated positive sales growth, with increases of approximately 6% and 2% year-over-year in 1Q25 and 2Q25, respectively, and projected growth of about 4% and 2% for 3Q25 and 4Q25, which suggests a recovering demand in the medical equipment sector. Additionally, the company's strategic pricing initiatives are expected to contribute approximately 100 basis points to sales growth in both 2024 and 2025, further supporting its financial performance. Despite concerns regarding the sustainability of this growth as comparisons normalize in 2026, the company's diversified portfolio and recent acquisitions indicate a solid foundation for potential future success.
Bears say
Baxter International experienced a disappointing second quarter in 2025, with sales, margins, and earnings per share (EPS) all falling below consensus expectations. The company has faced challenges during the 2021-2023 period, marked by both external factors and internal operational missteps, resulting in mixed quarterly performances and revisions to negative guidance. Furthermore, sales softness, along with manufacturing inefficiencies and an unfavorable product mix, contributed to gross margins of 40.7%, which missed consensus estimates of 42.7% and 42.6%, while operating margins at 15.1% also fell short by over 100 basis points.
This aggregate rating is based on analysts' research of Baxter and is not a guaranteed prediction by Public.com or investment advice.
Baxter (BAX) Analyst Forecast & Price Prediction
Start investing in Baxter (BAX)
Order type
Buy in
Order amount
Est. shares
0 shares